Gene	Named Alleles	CPIC Phenotypes	CPIC Activity Scores	DPWG Phenotyeps
ABCG2	rs2231142 reference (G);rs2231142 variant (T)	Decreased Function;Normal Function;Poor Function		
CACNA1S	Reference;c.520C>T;c.3257G>A	Malignant Hyperthermia Susceptibility;Uncertain Susceptibility		
CFTR	711+3A->G;2789+5G->A;3272-26A->G;3849+10kbC->T;A455E;A1067T;D110E;D110H;D579G;D1152H;D1270N;E56K;E193K;E831X;F1052V;F1074L;G178R;G551D;G551S;G1069R;G1244E;G1349D;K1060T;L206W;P67L;R74W;R117C;R117H;R347H;R352Q;R1070Q;R1070W;S549N;S549R(A>C);S549R(T>G);S945L;S977F;S1251N;S1255P;ivacaftor non-responsive CFTR sequence	ivacaftor non-responsive in CF patients;ivacaftor responsive in CF patients		
CYP2B6	*1;*2;*3;*4;*5;*6;*7;*8;*9;*10;*11;*12;*13;*14;*15;*17;*18;*19;*20;*21;*22;*23;*24;*25;*26;*27;*28;*31;*32;*33;*34;*35;*36;*37;*38;*39;*40;*41;*42;*43;*44;*45;*46;*47;*48;*49	Indeterminate;Intermediate Metabolizer;Normal Metabolizer;Poor Metabolizer;Rapid Metabolizer;Ultrarapid Metabolizer		Intermediate Metabolizer;Normal Metabolizer;Poor Metabolizer
CYP2C19	*1;*2;*3;*4;*5;*6;*7;*8;*9;*10;*11;*12;*13;*14;*15;*16;*17;*18;*19;*22;*23;*24;*25;*26;*28;*29;*30;*31;*32;*33;*34;*35;*38;*39	Indeterminate;Intermediate Metabolizer;Likely Intermediate Metabolizer;Likely Poor Metabolizer;Normal Metabolizer;Poor Metabolizer;Rapid Metabolizer;Ultrarapid Metabolizer		Intermediate Metabolizer;Normal Metabolizer;Poor Metabolizer;Ultrarapid Metabolizer
CYP2C9	*1;*2;*3;*4;*5;*6;*7;*8;*9;*10;*11;*12;*13;*14;*15;*16;*17;*18;*19;*20;*21;*22;*23;*24;*25;*26;*27;*28;*29;*30;*31;*32;*33;*34;*35;*36;*37;*38;*39;*40;*41;*42;*43;*44;*45;*46;*47;*48;*49;*50;*51;*52;*53;*54;*55;*56;*57;*58;*59;*60;*61;*62;*63;*64;*65;*66;*67;*68;*69;*70;*71;*72;*73;*74;*75;*76;*77;*78;*79;*80;*81;*82;*83;*84;*85	Indeterminate;Intermediate Metabolizer;Normal Metabolizer;Poor Metabolizer	0.0;0.5;1.0;1.5;2.0	Intermediate Metabolizer;Normal Metabolizer;Poor Metabolizer
CYP2D6	*1;*1x2;*1x≥3;*2;*2x2;*2x≥3;*3;*3x2;*4;*4x2;*4x≥3;*5;*6;*6x2;*7;*8;*9;*9x2;*10;*10x2;*11;*12;*13;*14;*15;*17;*17x2;*18;*19;*20;*21;*22;*23;*24;*25;*26;*27;*28;*29;*29x2;*30;*31;*32;*33;*34;*35;*35x2;*36;*36x2;*37;*38;*39;*40;*41;*41x2;*41x3;*42;*43;*43x2;*44;*45;*45x2;*46;*47;*48;*49;*50;*51;*52;*53;*54;*55;*56;*57;*58;*59;*60;*61;*62;*63;*64;*65;*68;*69;*70;*71;*72;*73;*74;*75;*81;*82;*83;*84;*85;*86;*87;*88;*89;*90;*91;*92;*93;*94;*95;*96;*97;*98;*99;*100;*101;*102;*103;*104;*105;*106;*107;*108;*109;*110;*111;*112;*113;*114;*115;*116;*117;*118;*119;*120;*121;*122;*123;*124;*125;*126;*127;*128;*129;*130;*131;*132;*133;*134;*135;*136;*137;*138;*139;*140;*141;*142;*143;*144;*145;*146;*146x2;*147;*148;*149;*152;*153;*154;*155;*156;*157;*158;*159;*160;*161;*162;*163	Indeterminate;Intermediate Metabolizer;Normal Metabolizer;Poor Metabolizer;Ultrarapid Metabolizer	0.0;0.25;0.5;0.75;1.0;1.25;1.5;1.75;2.0;2.25;2.5;2.75;3.0;4.0;≥3.0;≥3.25;≥3.5;≥3.75;≥4.0;≥5.0;≥6.0	Intermediate Metabolizer;Normal Metabolizer;Poor Metabolizer
CYP3A4	*1;*2;*3;*4;*5;*6;*7;*8;*9;*10;*11;*12;*13;*14;*15;*16;*17;*18;*19;*20;*21;*22;*23;*24;*26;*28;*29;*30;*31;*32;*33;*34;*35;*37;*38			Intermediate Metabolizer;Normal Metabolizer;Poor Metabolizer
CYP3A5	*1;*3;*6;*7;*8;*9	Indeterminate;Intermediate Metabolizer;Normal Metabolizer;Poor Metabolizer;Possible Intermediate Metabolizer		
CYP4F2	*1;*2;*3;*4;*5;*6;*7;*8;*9;*10;*11;*12;*13;*14;*15			
DPYD	Reference;c.46C>G;c.61C>T;c.62G>A;c.85T>C (*9A);c.295_298delTCAT (*7);c.313G>A;c.343A>G;c.451A>G;c.496A>G;c.498G>A;c.525G>A;c.557A>G;c.601A>C;c.632A>G;c.703C>T (*8);c.775A>G;c.868A>G;c.929T>C;c.934C>T;c.967G>A;c.1003G>T (*11);c.1024G>A;c.1057C>T;c.1108A>G;c.1129-5923C>G, c.1236G>A (HapB3);c.1156G>T (*12);c.1180C>T;c.1181G>T;c.1218G>A;c.1260T>A;c.1278G>T;c.1294G>A;c.1314T>G;c.1349C>T;c.1358C>G;c.1371C>T;c.1403C>A;c.1475C>T;c.1484A>G;c.1519G>A;c.1543G>A;c.1577C>G;c.1601G>A (*4);c.1615G>A;c.1627A>G (*5);c.1679T>G (*13);c.1682G>T;c.1774C>T;c.1775G>A;c.1777G>A;c.1796T>C;c.1896T>C;c.1898delC (*3);c.1905+1G>A (*2A);c.1905C>G;c.1906A>C;c.1990G>T;c.2021G>A;c.2161G>A;c.2186C>T;c.2194G>A (*6);c.2195T>G;c.2279C>T;c.2303C>A;c.2336C>A;c.2482G>A;c.2582A>G;c.2623A>C;c.2639G>T;c.2656C>T;c.2657G>A (*9B);c.2846A>T;c.2872A>G;c.2915A>G;c.2921A>T;c.2933A>G;c.2977C>T;c.2978T>G;c.2983G>T (*10);c.3049G>A;c.3061G>C;c.3067C>A	Intermediate Metabolizer;Normal Metabolizer;Poor Metabolizer	0.0;0.5;1.0;1.5;2.0	
F5	rs6025 C;rs6025 T (Factor V Leiden)			Factor V Leiden absent;Factor V Leiden heterozygous;Factor V Leiden homozygous
G6PD	202G>A_376A>G_1264C>G;A;A- 202A_376G;A- 680T_376G;A- 968C_376G;Aachen;Abeno;Acrokorinthos;Alhambra;Amazonia;Amiens;Amsterdam;Anadia;Ananindeua;Andalus;Arakawa;Asahi;Asahikawa;Aures;Aveiro;B (reference);Bajo Maumere;Bangkok;Bangkok Noi;Bao Loc;Bari;Belem;Beverly Hills, Genova, Iwate, Niigata, Yamaguchi;Brighton;Buenos Aires;Cairo;Calvo Mackenna;Campinas;Canton, Taiwan-Hakka, Gifu-like, Agrigento-like;Cassano;Chatham;Chikugo;Chinese-1;Chinese-5;Cincinnati;Cleveland Corum;Clinic;Coimbra Shunde;Cosenza;Costanzo;Covao do Lobo;Crispim;Dagua;Durham;Farroupilha;Figuera da Foz;Flores;Fukaya;Fushan;Gaohe;Georgia;Gidra;Gond;Guadalajara;Guangzhou;Haikou;Hammersmith;Harilaou;Harima;Hartford;Hechi;Hermoupolis;Honiara;Ierapetra;Ilesha;Insuli;Iowa, Walter Reed, Springfield;Iwatsuki;Japan, Shinagawa;Kaiping, Anant, Dhon, Sapporo-like, Wosera;Kalyan-Kerala, Jamnaga, Rohini;Kambos;Kamiube, Keelung;Kamogawa;Kawasaki;Kozukata;Krakow;La Jolla;Lages;Lagosanto;Laibin;Lille;Liuzhou;Loma Linda;Ludhiana;Lynwood;Madrid;Mahidol;Malaga;Manhattan;Mediterranean, Dallas, Panama, Sassari, Cagliari, Birmingham;Metaponto;Mexico City;Miaoli;Minnesota, Marion, Gastonia, LeJeune;Mira d'Aire;Mizushima;Montalbano;Montpellier;Mt Sinai;Munich;Murcia Oristano;Musashino;Namouru;Nankang;Nanning;Naone;Nara;Nashville, Anaheim, Portici;Neapolis;Nice;Nilgiri;No name;North Dallas;Olomouc;Omiya;Orissa;Osaka;Palestrina;Papua;Partenope;Pawnee;Pedoplis-Ckaro;Piotrkow;Plymouth;Praha;Puerto Limon;Quing Yan;Radlowo;Rehevot;Rignano;Riley;Riverside;Roubaix;S. Antioco;Salerno Pyrgos;Santa Maria;Santiago;Santiago de Cuba, Morioka;Sao Borja;Seattle, Lodi, Modena, Ferrara II, Athens-like;Seoul;Serres;Shenzen;Shinshu;Sibari;Sierra Leone;Sinnai;Songklanagarind;Split;Stonybrook;Sugao;Sumare;Sunderland;Surabaya;Suwalki;Swansea;Taipei, Chinese-3;Telti/Kobe;Tenri;Tokyo, Fukushima;Toledo;Tomah;Tondela;Torun;Tsukui;Ube Konan;Union,Maewo, Chinese-2, Kalo;Urayasu;Utrecht;Valladolid;Vancouver;Vanua Lava;Viangchan, Jammu;Volendam;Wayne;West Virginia;Wexham;Wisconsin;Yunan	Deficient;Deficient with CNSHA;Indeterminate;Normal;Variable		
IFNL3	rs12979860 reference (C);rs12979860 variant (T)			
MT-RNR1	663A>G;669T>C;747A>G;786G>A;807A>C;807A>G;827A>G;839A>G;896A>G;930A>G;951G>A;960C>del;961T>G;961T>del;961T>del+Cn;988G>A;1095T>C;1189T>C;1243T>C;1494C>T;1520T>C;1537C>T;1555A>G;1556C>T;Reference	increased risk of aminoglycoside-induced hearing loss;normal risk of aminoglycoside-induced hearing loss;uncertain risk of aminoglycoside-induced hearing loss		
NUDT15	*1;*2;*3;*4;*5;*6;*7;*8;*9;*10;*11;*12;*13;*14;*15;*16;*17;*18;*19;*20	Indeterminate;Intermediate Metabolizer;Normal Metabolizer;Poor Metabolizer;Possible Intermediate Metabolizer		Intermediate Metabolizer;Normal Metabolizer;Poor Metabolizer
RYR1	Reference;c.103T>C;c.130C>T;c.487C>T;c.488G>T;c.742G>A;c.742G>C;c.982C>T;c.1021G>A;c.1021G>C;c.1201C>T;c.1209C>G;c.1565A>C;c.1589G>A;c.1597C>T;c.1598G>A;c.1654C>T;c.1840C>T;c.1841G>T;c.6487C>T;c.6488G>A;c.6502G>A;c.6617C>G;c.6617C>T;c.7007G>A;c.7042_7044delGAG;c.7048G>A;c.7063C>T;c.7124G>C;c.7282G>A;c.7300G>A;c.7304G>A;c.7354C>T;c.7360C>T;c.7361G>A;c.7372C>T;c.7373G>A;c.7522C>G;c.7522C>T;c.7523G>A;c.9310G>A;c.11969G>T;c.14387A>G;c.14477C>T;c.14497C>T;c.14512C>G;c.14545G>A;c.14582G>A;c.14693T>C	Malignant Hyperthermia Susceptibility;Uncertain Susceptibility		
SLCO1B1	*1;*2;*3;*4;*5;*6;*7;*8;*9;*10;*11;*12;*13;*14;*15;*16;*19;*20;*23;*24;*25;*26;*27;*28;*29;*30;*31;*32;*33;*34;*36;*37;*38;*39;*40;*41;*42;*43;*44;*45;*46;*47	Decreased Function;Increased Function;Indeterminate;Normal Function;Poor Function;Possible Decreased Function		
TPMT	*1;*2;*3A;*3B;*3C;*4;*5;*6;*7;*8;*9;*10;*11;*12;*13;*14;*15;*16;*17;*18;*19;*20;*21;*22;*23;*24;*25;*26;*27;*28;*29;*30;*31;*32;*33;*34;*35;*36;*37;*38;*39;*40;*41;*42;*43;*44	Indeterminate;Intermediate Metabolizer;Normal Metabolizer;Poor Metabolizer;Possible Intermediate Metabolizer		Intermediate Metabolizer;Normal Metabolizer;Poor Metabolizer
UGT1A1	*1;*6;*27;*28;*36;*37;*80;*80+*28;*80+*37	Indeterminate;Intermediate Metabolizer;Normal Metabolizer;Poor Metabolizer		Intermediate Metabolizer;Normal Metabolizer;Poor Metabolizer
VKORC1	rs9923231 reference (C);rs9923231 variant (T)			
